Optimization of interferon gamma ELISPOT assay to detect human cytomegalovirus specific T-cell responses in solid organ transplants

Journal of Virological Methods

Volumn 196, Issue , 2014, Pages 157-162

  Abate, Davide ^a   Saldan, Alda ^a   Forner, Gabriella ^a   Tinto, Daniel ^a   Bianchin, Alice ^a   Palu, Giorgio ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

Cell mediated immunity; ELISPOT; Human cytomegalovirus; Interferon gamma releasing assay; T cell; Transplantation

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; IMMUNOGLOBULIN G; IONOMYCIN; PHORBOL 13 ACETATE 12 MYRISTATE; POKEWEED MITOGEN;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; ROSETTE FORMATION; SERODIAGNOSIS; VIRUS ACTIVATION; VIRUS DETECTION; VIRUS PARTICLE;

AZA; AZATHIOPRINE; CELL MEDIATED IMMUNITY; CELL-MEDIATED IMMUNITY; CMI; CMV; CONA; CONCANAVALIN A; CSA; CYCLOSPORINE A; ELISPOT; HLA; HUMAN CYTOMEGALOVIRUS; HUMAN LEUKOCYTE ANTIGEN; INTERFERON GAMMA RELEASING ASSAY; MMF; MYCOPHENOLIC ACID; PBMCS; PERIPHERAL BLOOD MONONUCLEAR CELLS; PFU; PHA; PHORBOL MYRISTATE ACETATE AND IONOMYCIN; PHYTOHEMOAGGLUTININ; PKC; PLAQUE FORMING UNIT; PMA/IONO; POKEWEED MITOGEN; PROTEIN KINASE C; PWM; T-CELL; TRANSPLANTATION;

ADULT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; ENZYME-LINKED IMMUNOSPOT ASSAY; HUMANS; INTERFERON-GAMMA; T-LYMPHOCYTES; TRANSPLANTATION; TRANSPLANTS;

EID: 84896974962     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2013.10.036     Document Type: Article

References (44)

1. Abate D., Cesaro S., Cofano S., Fiscon M., Saldan A., Varotto S., Mengoli C., Pillon M., Calore E., Biasolo M.A., Cusinato R., Barzon L., Messina C., Carli M., Palu G. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients. Transplantation 2012, 93:536-542.
2. Abate D., Fiscon M., Saldan A., Cofano S., Mengoli C., Sgarabotto D., d'Agostino C., Barzon L., Cusinato R., Toscano G., Feltrin G., Gambino A., Gerosa G., Palu G. Human cytomegalovirus-specific T-cell immune reconstitution in preemptively treated heart transplant recipients identifies subjects at critical risk for infection. J. Clin. Microbiol. 2012, 50:1974-1980.
3. Abate D., Saldan A., Fiscon M., Cofano S., Paciolla A., Furian L., Ekser B., Biasolo M.A., Cusinato R., Mengoli C., Bonfante L., Rossi B., Rigotti P., Sgarabotto D., Barzon L., Palu G. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients. J. Infect. Dis. 2010, 202:585-594.
4. Abate D., Saldan A., Mengoli C., Fiscon M., Silvestre C., Fallico L., Peracchi M., Furian L., Cusinato R., Bonfante L., Rossi B., Marchini F., Sgarabotto D., Rigotti P., Palu G. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients. J. Clin. Microbiol. 2013, 51:2501-2507.
5. Abate D.A., Watanabe S., Mocarski E.S. Major human cytomegalovirus structural protein pp65 (ppUL83) prevents interferon response factor 3 activation in the interferon response. J. Virol. 2004, 78:10995-11006.
6. Bestard O., Lucia M., Crespo E., Van Liempt B., Palacio D., Melilli E., Torras J., Llaudo I., Cerezo G., Taco O., Gil-Vernet S., Grinyo J.M., Cruzado J.M. Pretransplant immediately early-1-specific T cell responses provide protection for CMV infection after kidney transplantation. Am. J. Transplant. 2013.
7. Clari M.A., Aguilar G., Benet I., Belda J., Gimenez E., Bravo D., Carbonell J.A., Henao L., Navarro D. Evaluation of cytomegalovirus (CMV)-specific T-cell immunity for the assessment of the risk of active CMV infection in non-immunosuppressed surgical and trauma intensive care unit patients. J. Med. Virol. 2013.
8. Costa C., Saldan A., Sinesi F., Sidoti F., Balloco C., Simeone S., Piceghello A., Mantovani S., Di Nauta A., Solidoro P., Cavallo R. The lack of cytomegalovirus-specific cellular immune response may contribute to the onset of organ infection and disease in lung transplant recipients. Int. J. Immunopathol. Pharmacol. 2012, 25:1003-1009.
9. Courcelle C.T., Courcelle J., Prichard M.N., Mocarski E.S. Requirement for uracil-DNA glycosylase during the transition to late-phase cytomegalovirus DNA replication. J. Virol. 2001, 75:7592-7601.
10. Dunn H.S., Haney D.J., Ghanekar S.A., Stepick-Biek P., Lewis D.B., Maecker H.T. Dynamics of CD4 and CD8 T cell responses to cytomegalovirus in healthy human donors. J. Infect. Dis. 2002, 186:15-22.
11. Egli A., Binet I., Binggeli S., Jager C., Dumoulin A., Schaub S., Steiger J., Sester U., Sester M., Hirsch H.H. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J. Transl. Med. 2008, 6:29.
12. Egli A., Silva M., O'Shea D., Wilson L.E., Baluch A., Lisboa L.F., Hidalgo L.G., Kumar D., Humar A. An analysis of regulatory T-cell and Th-17 cell dynamics during cytomegalovirus replication in solid organ transplant recipients. PLoS ONE 2012, 7:e43937.
13. Emery V.C., Asher K., Sanjuan Cde J. Importance of the cytomegalovirus seropositive recipient as a contributor to disease burden after solid organ transplantation. J. Clin. Virol. 2012, 54:125-129.
14. Fishman J.A. Infection in solid-organ transplant recipients. N. Engl. J. Med. 2007, 357:2601-2614.
15. Fishman J.A., Emery V., Freeman R., Pascual M., Rostaing L., Schlitt H.J., Sgarabotto D., Torre-Cisneros J., Uknis M.E. Cytomegalovirus in transplantation - challenging the status quo. Clin. Transplant. 2007, 21:149-158.
16. Fulton B., Markham A. Mycophenolate mofetil: a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 1996, 51:278-298.
17. Gerna G., Lilleri D. Monitoring transplant patients for human cytomegalovirus: diagnostic update. Herpes 2006, 13:4-11.
18. Gerna G., Lilleri D., Fornara C., Comolli G., Lozza L., Campana C., Pellegrini C., Meloni F., Rampino T. Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am. J. Transplant. 2006, 6:2356-2364.
19. Hill P.C., Jeffries D.J., Brookes R.H., Fox A., Jackson-Sillah D., Lugos M.D., Donkor S.A., de Jong B.C., Corrah T., Adegbola R.A., McAdam K.P. Using ELISPOT to expose false positive skin test conversion in tuberculosis contacts. PLoS ONE 2007, 2:e183.
20. Kotton C.N. CMV: prevention, diagnosis and therapy. Am. J. Transplant. 2013, 13(Suppl. 3):24-40.
21. Kumar D., Chernenko S., Moussa G., Cobos I., Manuel O., Preiksaitis J., Venkataraman S., Humar A. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am. J. Transplant. 2009, 9:1214-1222.
22. Lisboa L.F., Kumar D., Wilson L.E., Humar A. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation 2012, 93:195-200.
23. Maltzman J.S., Koretzky G.A. Azathioprine: old drug, new actions. J. Clin. Invest. 2003, 111:1122-1124.
24. Manning W.C., Stoddart C.A., Lagenaur L.A., Abenes G.B., Mocarski E.S. Cytomegalovirus determinant of replication in salivary glands. J. Virol. 1992, 66:3794-3802.
25. Manuel O., Husain S., Kumar D., Zayas C., Mawhorter S., Levi M.E., Kalpoe J., Lisboa L., Ely L., Kaul D.R., Schwartz B.S., Morris M.I., Ison M.G., Yen-Lieberman B., Sebastian A., Assi M., Humar A. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin. Infect. Dis. 2013, 56:817-824.
26. Manuel O., Kumar D. QuantiFERON-TB Gold assay for the diagnosis of latent tuberculosis infection. Expert Rev. Mol. Diagn. 2008, 8:247-256.
27. Mattes F.M., Vargas A., Kopycinski J., Hainsworth E.G., Sweny P., Nebbia G., Bazeos A., Lowdell M., Klenerman P., Phillips R.E., Griffiths P.D., Emery V.C. Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation. Am. J. Transplant. 2008, 8:990-999.
28. Mocarski E.S., Shenk T., Pass R.F. Cytomegaloviruses and their replication 2007, Lippincott Williams & Wilkins, Philadelphia.
29. Nebbia G., Mattes F.M., Smith C., Hainsworth E., Kopycinski J., Burroughs A., Griffiths P.D., Klenerman P., Emery V.C. Polyfunctional cytomegalovirus-specific CD4+ and pp65 CD8+ T cells protect against high-level replication after liver transplantation. Am. J. Transplant. 2008, 8:2590-2599.
30. Nickel P., Bestard O., Volk H.D., Reinke P. Diagnostic value of T-cell monitoring assays in kidney transplantation. Curr. Opin. Organ Transplant. 2009, 14:426-431.
31. Nickel P., Bold G., Presber F., Biti D., Babel N., Kreutzer S., Pratschke J., Schonemann C., Kern F., Volk H.D., Reinke P. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function. Transpl. Immunol. 2009, 20:238-242.
32. Pai M., Riley L.W., Colford J.M. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect. Dis. 2004, 4:761-776.
33. Pai M., Zwerling A., Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann. Intern. Med. 2008, 149:177-184.
34. Razonable R.R. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am. J. Health Syst. Pharm. 2005, 62:S7-S13.
35. Saederup N., Lin Y.C., Dairaghi D.J., Schall T.J., Mocarski E.S. Cytomegalovirus-encoded beta chemokine promotes monocyte-associated viremia in the host. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:10881-10886.
36. Schmolke S., Kern H.F., Drescher P., Jahn G., Plachter B. The dominant phosphoprotein pp65 (UL83) of human cytomegalovirus is dispensable for growth in cell culture. J. Virol. 1995, 69:5959-5968.
37. Sester M., Sotgiu G., Lange C., Giehl C., Girardi E., Migliori G.B., Bossink A., Dheda K., Diel R., Dominguez J., Lipman M., Nemeth J., Ravn P., Winkler S., Huitric E., Sandgren A., Manissero D. Interferon-gamma release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur. Respir. J. 2011, 37:100-111.
38. Sinclair E., Black D., Epling C.L., Carvidi A., Josefowicz S.Z., Bredt B.M., Jacobson M.A. CMV antigen-specific CD4+ and CD8+ T cell IFNgamma expression and proliferation responses in healthy CMV-seropositive individuals. Viral Immunol. 2004, 17:445-454.
39. Smith J.G., Joseph H.R., Green T., Field J.A., Wooters M., Kaufhold R.M., Antonello J., Caulfield M.J. Establishing acceptance criteria for cell-mediated-immunity assays using frozen peripheral blood mononuclear cells stored under optimal and suboptimal conditions. Clin. Vaccine Immunol. 2007, 14:527-537.
40. Stoddart C.A., Cardin R.D., Boname J.M., Manning W.C., Abenes G.B., Mocarski E.S. Peripheral blood mononuclear phagocytes mediate dissemination of murine cytomegalovirus. J. Virol. 1994, 68:6243-6253.
41. Sylwester A.W., Mitchell B.L., Edgar J.B., Taormina C., Pelte C., Ruchti F., Sleath P.R., Grabstein K.H., Hosken N.A., Kern F., Nelson J.A., Picker L.J. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 2005, 202:673-685.
42. Walker S., Fazou C., Crough T., Holdsworth R., Kiely P., Veale M., Bell S., Gailbraith A., McNeil K., Jones S., Khanna R. Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV. Transpl. Infect. Dis. 2007, 9:165-170.
43. Westall G.P., Mifsud N.A., Kotsimbos T. Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity. Am. J. Transplant. 2008, 8:1749-1754.
44. Widmann T., Sester U., Gartner B.C., Schubert J., Pfreundschuh M., Kohler H., Sester M. Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation. PLoS ONE 2008, 3:e3634.